PDB44 EXPLORING DIFFERENCES IN PATIENT VERSUS PUBLIC PREFERENCES IN HEALTH UTILITIES:A QUALITATIVE STUDY  by Lloyd, A et al.
A237Abstracts
PDB41
EFFECT OF COMPLICATIONS ON HEALTH RELATED
QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED
DIABETIC PATINETS
Brodszky V1, Péntek M2, Majer I1, Karpati K1, Lepp-Gazdag A1,
Jelics N1, Gulácsi L1
1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc
County Hospital, Kistarcsa, Hungary
OBJECTIVES: The main goal of the study is to assess the health
related quality of life of Hungarian insulin treated patients in
order to offer country-speciﬁc data for cost-utility analysis. Also
to study the impact of diabetic complications on utility loss.
METHODS: In 2004 a multicenter cross-sectional questionnaire
survey was conducted among 480 insulin treated diabetic
patients in Hungary. Validated Hungarian version of the EQ-5D
questionnaire was used to assess health status. RESULTS:
Patients main characteristics were: women 56%, type 1 diabetes
58%, mean age 53 years, disease duration 18.6 years. Average
EQ-5D score was 0.7661, in subgroups of patients without, with
macrovascular, with microvascular and with both complications
were 0.84 (SD 0.23), 0.65 (SD 0.33), 0.70 (SD 0.30) and 0.61
(SD 0.34), respectively. Categorizing patients by type of diabetes,
EQ-5D scores similarly were 0.84 (SD 0.20), 0.77 (SD 0.16),
0.77 (SD 0.24), 0.78 (SD 0.25) in Type 1, and 0.72 (SD 0.3),
0,64 (SD 0.34), 0.67 (SD 0.32), 0.60 (SD 0.35) in Type 2.
Average EQ-5D of patients with nephropathy was 0.66 (SD
0.35), with retinopathy was 0.70 (SD 0,30) and with neuropa-
thy was 0.61 (SD 0.34). In absence of complications, the rate of
patients reporting problem in mobility, self-care, everyday activ-
ities, pain or anxiety were 18%, 4%, 14%, 33%, and 32%. Con-
trarily, these rates were 68%, 28%, 44%, 70%, and 56% in the
presence of both micro- and macrovascular disorders. CON-
CLUSIONS: Both microvascular and macrovascular complica-
tions has negative impact on health related quality of life in
insulin-dependent diabetic population in Hungary. Neuropathy
has the most negative effect. Complications in type 2 diabetes
induce lower EQ-5D scores than in type 1. Mobility dimension
of EQ-5D is the most affected by diabetic complications.
PDB42
PATIENT AND PHYSICIAN DRIVERS OF HEALTH-RELATED
QUALITY LIFE OF PATIENTS WITH TYPE 2 DIABETES IN
PRIMARY CARE IN SPAIN
Yurgin NR1, Secnik K1, Lara N2, Badia X2, Dilla T3, Cordero LA3
1Eli Lilly and Company, Indianapolis, IN, USA, 2Health Outcomes
Research Europe, Barcelona, Spain, 3Eli Lilly Spain, Alcobendas, Spain
OBJECTIVES: This study describes the health related quality of
life (HRQoL) of type 2 diabetic patients in Spain and explores
predictors of patients’ and physicians’ ratings of patients’
HRQoL. METHODS: Multicenter, naturalistic study of type 2
diabetes patients with a diagnosis longer than one year. Patients
were consecutively included in the study among those attending
any of the selected 30 Primary Care Centers distributed through-
out Spain Sociodemographic and clinical variables were col-
lected. Patients ﬁlled out the EuroQoL-5D questionnaire
(EQ-5D) and physicians ﬁlled out the EQ-5D proxy version.
Data analysis included two lineal regression models to evaluate
patients’ and physicians’ drivers of perceived HRQoL.
RESULTS: A totla of 294 patients were included in the study.
The mean age of the study participants was 67.5 and the mean
duration of diabetes was 9.9 years. The mean EQ-5D index score
was 0.71 (0.26) for patients’ self-measurement and 0.75 (0.23)
for physicians’ proxy measurement of patients’ HRQoL. For
both groups, pain/discomfort was the dimension with the highest
reported problems (>57%). Overall, there was good agreement
in the 5 EQ-5D dimensions between patients’ and physicians’
responses (weighted Kappa = 0.67–0.72), with only
anxiety/depression showing moderate agreement (0.51). Being
older, not having completed at least primary studies, being on
insulin and having microvascular and/or macrovascular compli-
cations, in both models, signiﬁcantly decreased (p < 0.05)
HRQoL. Additionally, in the patient regression model being
female also lead to signiﬁcantly lower (p < 0.05) patient reported
HRQoL differences. CONCLUSIONS: Pain/discomfort was
reported as the dimension with the most problems for patients
with Type 2 diabetes in Spain Patients’ and physicians’ percep-
tion about diabetic patients HRQoL tended to have good agree-
ment. Results suggest, in the absence of direct patient assessment,
a proxy version of the EQ-5D administered to primary care
physicians can provide a reasonable assessment of the HRQoL
of their patients with type 2 diabetes.
PDB43
EFFECT OF INSULIN GLARGINE AND NPH ON QUALITY OF
LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Gupta K, Gupta U, Singh N
Maulana Azad Medical College, New Delhi, India
OBJECTIVES: Intensive treatment to achieve targeted glycemic
index (HbA1c < 7% and FBG < 140 mg %) with the help of early
initiation of basal insulin in addition to oral hypoglycemic agents
has been proposed for Type 2 Diabetes mellitus. Insulin glargine
has been reported to be as efﬁcacious as NPH insulin along with
oral hypoglycemic agents in type 2 Diabetes mellitus. However,
its impact on quality of life has not been evaluated. METHODS:
Forty patients of type 2 diabetes mellitus on two or more oral
hypoglycemic agents for more than three months and unable to
achieve targeted glycemic index were enrolled and randomized
in a open label comparative trial into two groups, 20 patients
each, taking either insulin glargine or NPH insulin in combina-
tion to previous treatment. The end points evaluated were
glycemic index, hypoglycemic episodes impact on treatment sat-
isfaction, Well being and Quality of life. RESULTS: Both the
treatment groups equally achieved euglycemic levels. The mean
decrease in HbA1c level in both groups was same but more
number of patients (15 vs. 10) were able to achieve fair to good
glycemic control in insulin glargine group. Total episodes of
hypoglycemia were 50% lesser in Insulin glargine group (13 vs.
26) with no severe and lesser nocturnal episodes. Quality of life
parameters improved in both groups but signiﬁcantly higher in
insulin glargine group (Treatment satisfaction: 43.75 ± 2.05 vs.
34.44 ± 1.68; General well being: 27.1 ± 2.37 vs. 16.75 ± 1.58;
Total satisfaction: 35.50 ± 2.25 vs. 23.81 ± 1.92). Higher number
of people had overall good to excellent rating of quality of life
(18 vs.10).CONCLUSIONS: Achievement of target glycemic
control was similar in both insulin regimens however, patients
on insulin glargine had signiﬁcantly lesser number of hypo-
glycemic episodes and far better treatment satisfaction, sense of
well being and quality of life.
PDB44
EXPLORING DIFFERENCES IN PATIENT VERSUS PUBLIC
PREFERENCES IN HEALTH UTILITIES:A QUALITATIVE STUDY
Lloyd A1, Nafees B2, Rousculp M3, Girach A4,Ahmad A5
1United Biosource Corporation, London, UK, 2UBC, London, UK, 3Eli
Lilly and Company, Indianapolis, IN, USA, 4Eli Lilly and Company,
Surrey, UK, 5Royal Liverpool University Hospital, Liverpool, UK
OBJECTIVE: This pilot study aimed to collect health utility and
qualitative data from diabetic retinopathy (DR) patients and
members of general public regarding the impact of DR and
varying degrees of vision loss. This data was used to help develop
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a subsequent valuation study to derive utility values for DR.
METHODS: Health state descriptions of visual acuity (VA) loss
were developed based on the ﬁndings of in-depth interviews with
diabetelogists and ophthalmologists. They represented visual
acuity levels in the best corrected eye (6/6-6/9, 6/12-6/18, 6/24-
6/36, 6/60-6/120, counting ﬁngers and hand motions). Two DR
patients in each VA level (N = 10) and members of general public
(N = 10) took part in standard gamble (SG) interviews and a
cognitive debrief interview. The interview attempted to explore
participants’ preferences around aspects of the health states. SG
data were summarised and transcribed interviews underwent
qualitative analysis of content. Qualitative data analysis
attempted to explore the rationale for SG valuations and the dif-
ferences in patient and public preferences. RESULTS: SG data
showed that patients value vision loss and its impact on health-
related quality of life differently to members of the general
public. This was further supported by the ﬁndings of the quali-
tative interviews in which patients’ provided personal insight
into their own experience of the disease and its impact on their
health-related quality of life. Qualitative analysis illustrated the
different perceptions of health states. CONCLUSION: The dif-
ferences in patients’ and societal views of vision loss associated
with DR and its impact on functioning were explored. Valuable
insights were gained into the signiﬁcant determinants of patient
and public preferences which have implications for valuation
studies. This information will be particularly important in under-
standing the decision making process that drives people’s choice.
PDB45
EXPERIENCE OF HYPOGLYCEMIA IS SIGNIFICANTLY
ASSOCIATED WITH LOWER QUALITY OF LIFE (EUROQOL)
IN DIABETIC PATIENTS TREATED WITH METFORMIN (MF) IN
COMBINATION WITH A SULPHONYLUREA (SU) IN FRANCE
Mavros P, Lyu R,Yin D
Merck & Co., Inc, Whitehouse Station, NJ, USA
OBJECTIVES: This study evaluated the experience of hypo-
glycemia and its impact on QoL among diabetic patients treated
with MF in combination with a SU in France. METHODS: This
is an observational, cross sectional multi-center survey con-
ducted in 2005. Diabetic patients (≥35 years old) treated with
MF in combination with SU for ≥6 months prior to study enroll-
ment were included. Excluded were patients receiving insulin,
treated for hepatitis or HIV, or having gestational diabetes. Case
report forms were developed for collection of patients’ medical
record, experience of hypoglycemia, and general QoL as mea-
sured by EQ-5D. The un-weighted scoring rule was used to
obtain summary EuroQoL scores. Adjusted linear regression
analysis was used to evaluate the effect of hypoglycemia on
patients’ QoL controlling for demographic and medical charac-
teristics. RESULTS: Four-hundred patients were recruited:
average age was 62 years and 46% were female; 45% of the
patients have been diagnosed with diabetes for >7 years. One-
hundred-thirty-six (34%) patients reported at least one episode
of hypoglycemia during the previous 6 months: 79 (58%) expe-
rienced mild/moderate symptoms, 53 (39%) had both mild/mod-
erate and severe symptoms, and the remaining 3% had only
severe symptoms. More than half of those reported mild/mod-
erate symptoms, and >33% of those reported severe symptoms
had ≥3 hypoglycemic episodes during the 6-month period prior
to study enrollment. Patients with hypoglycemic episodes
reported signiﬁcantly lower EuroQoL scores relative to those
without any symptoms (0.7 vs. 0.8, p < 0.0001). After adjusting
for demographic and medical characteristics (age, gender, marital
status, education, co-morbid conditions) the reduction in the
EuroQoL score for those with any hypoglycemic symptoms was
0.08 (p = 0.0007) units. CONCLUSIONS: More than a third of
the study patients experienced one or more hypoglycemic symp-
toms. This study found that presence of hypoglycemic symptoms
is signiﬁcantly associated with lower QoL.
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QUANTIFYING THE IMPACT OF FEAR OF HYPOGLYCAEMIA
ON QUALITY OF LIFE
Walters N1, Gordois A1, Brown A1, Lindsay P2, Gonzalo F2,
Comas S2
1M-TAG Pty Ltd—A unit of IMS Health®, Chatswood, NSW,
Australia, 2Sanoﬁ-aventis Australia, Macquarie Park, NSW, Australia
OBJECTIVES: Hypoglycaemia is one of the most frequent acute
complications of type 1 diabetes. The fear and anxiety associ-
ated with experiencing hypoglycaemia may cause some diabet-
ics to deliberately allow their blood sugar to become elevated 
in order to avoid future events, thus risking long-term diabetic
complications. This trade-off between risks suggests that the psy-
chological impact of hypoglycaemia on quality of life may be
underestimated. This study’s prupose is to quantify the impact
of fear of hypoglycaemia on quality of life. METHODS: Eighty-
ﬁve type 1 diabetics completed the Hypoglycaemia Fear Survey
(HFS), and questions relating to the frequency and severity of
hypoglycaemic events. Respondents were categorised by whether
or not they had experienced a severe hypoglycaemic event in the
past three months. Key differences on the HFS were used to con-
struct ﬁve health states which described the behaviour, state of
mind and events experienced during a typical week for a type 1
diabetic: baseline; fear of non-severe hypoglycaemia with and
without a non-severe hypoglycaemic event; fear of severe hypo-
glycaemia with and without a severe hypoglycaemic event. A
total of 122 people from the general population evaluated the
ﬁve health states using the time-trade-off methodology. Short-
term disutilities during events and long-term disutilities due to
fear of future events were estimated as the differences between
health state utilities. RESULTS: Fear of severe hypoglycaemia
had a disutility value of −0.06 and fear of non-severe hypogly-
caemia had a disutility value of −0.01. A severe hypoglycaemic
event had a disutility value of −0.16, whilst the disutility associ-
ated with a non-severe hypoglycaemic event was −0.07. CON-
CLUSIONS: Fear of hypoglycaemia has a detrimental impact on
quality of life in diabetic patients beyond that of the event itself.
When comparing insulin therapies, the reduction in the incidence
of hypoglycaemia should be incorporated as an important
measure of treatment success.
PDB47
A USEFUL TOOL FOR EVALUATING THE FEAR OF INJECTING
AND SELF-TESTING IN DIABETIC PATIENTS:THE SPANISH
VERSION OF THE DIABETES FEAR OF INJECTING AND 
SELF-TESTING QUESTIONNAIRE (D-FISQ)
Rebollo P1, González P2, Baillo P3, Laporta F4, Martorell J5, Morís J1,
Rejas J2
1BAP Health Outcomes, Oviedo, Asturias, Spain, 2Pﬁzer Spain,
Alcobendas, Madrid, Spain, 3C.A.P. Cervera, Cervera, Lleida, Spain,
4C.S. La Roda, La Roda, Albacete, Spain, 5C.A.P. Guissona, Guissona,
Lleida, Spain
OBJECTIVE: To validate into Spanish and recalibrate the D-
FISQ, a 30-items 2-dimensions [Fear of self-injecting (FSI) and
self-testing (FST)], speciﬁc questionnaire for evaluating the fear
of injecting and self-testing in diabetic patients. METHODS:
Forward-backward translations in duplicate were carried out by
professional translators and revised by expert and non-expert
panels. Type 1 and 2 diabetic patients, both genders above 18
years were enrolled in 3 primary care centres. Spanish D-FISQ
